文献速递胸部肿瘤

意大利纳武利尤单抗扩展准入项目:从不吸烟与EGFR突变非鳞NSCLC患者结果

Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients.
PubMed 文献 · J Thorac Oncol · 2018-05-03

该研究基于意大利纳武利尤单抗扩展准入项目,纳入1588例经治晚期非鳞NSCLC患者,其中从不吸烟者305例(19.2%),EGFR突变阳性者102例(6.4%)。结果显示EGFR野生型、吸烟者的客观缓解率更高,但中位无进展生存期与总生存期在各亚组间无统计学显著差异。

要点

  • EGFR野生型客观缓解率19.6%高于突变型8.8%(p=0.007)。
  • 吸烟者客观缓解率21.5%高于从不吸烟者9.2%(p=0.0001)。
  • 各亚组间中位无进展生存期与总生存期无统计学显著差异。

核心结论

  • 非鳞NSCLC患者按EGFR突变状态与吸烟习惯可分为获益不同的亚组,值得进一步研究。

研究设计与样本

  • 意大利纳武利尤单抗扩展准入项目,纳武利尤单抗3 mg/kg每2周静脉给药,评估至少接受一剂治疗者的疗效与安全性。
  • 非鳞NSCLC患者共1588例,从不吸烟者305例(19.2%);1395例可评估EGFR状态,突变阳性102例(6.4%),其中从不吸烟者51例(50%)。

主要发现

  • EGFR野生型与突变型客观缓解率分别为19.6%与8.8%(p=0.007)。
  • 既往吸烟与当前吸烟者客观缓解率21.5%,从不吸烟者9.2%(p=0.0001)。
  • 从不吸烟者中EGFR野生型与突变型客观缓解率分别为11.0%与1.9%(p=0.04)。
  • 吸烟者中EGFR野生型与突变型客观缓解率分别为22.0%与20.6%,无显著差异。
  • 中位总生存期:EGFR野生型11个月 vs 突变型8.3个月;吸烟者11.6个月 vs 从不吸烟者10.0个月;从不吸烟者中野生型11.0个月 vs 突变型5.6个月;吸烟者中突变型14.1个月 vs 野生型11.3个月。

临床怎么用

  • 提示临床对非鳞NSCLC使用纳武利尤单抗时应结合EGFR突变状态与吸烟史评估可能的获益差异。

局限性

  • 为扩展准入项目数据,结论需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Nivolumab is the first checkpoint inhibitor approved for the treatment of nonsquamous NSCLC. We report results from the nivolumab Italian expanded access program focusing on never-smokers and patients with EGFR-mutant nonsqamous NSCLC. METHODS: Nivolumab (3 mg/kg intravenously every 2 weeks) was administered upon physicians' request to patients who had relapsed after one or more prior systemic treatments for stage IIIB/IV nonsquamous NSCLC. Efficacy and safety were evaluated in patients who received at least one dose of nivolumab. RESULTS: Of 1588 patients with nonsquamous NSCLC, 305 (19.2%) were never-smokers. EGFR status was available for 1395 patients. Of the 102 patients (6.4%) with EGFR mutation-positive tumors, 51 (50%) were never-smokers. The objective response rate was significantly higher in patients with wild-type EGFR than patients with EGFR-mutant tumors (19.6% versus 8.8% [p = 0.007]), in former and current smokers than in never-smokers (21.5% versus 9.2% [p = 0.0001]), and in never-smokers with wild-type EGFR than in never-smokers with mutant EGFR (11.0% versus 1.9% [p = 0.04]). There was no significant difference in objective response rate between smokers with wild-type EGFR and smokers with mutant EGFR (22.0% versus 20.6%). There was no statistically significant difference in median progression-free survival or in median overall survival. The median overall survival times were 11 months in patients with EGFR wild-type tumors versus 8.3 months in patients with EGFR-mutant tumors, 11.6 months in smokers versus 10.0 months in never-smokers, 11.0 months in never-smokers with EGFR wild-type tumors versus 5.6 months in never-smokers with EGFR-mutant tumors, and 14.1 months in smokers with EGFR-mutant tumors versus 11.3 months in smokers with EGFR wild-type tumors. CONCLUSIONS: The data on the Italian expanded access program in populations with nonsquamous NSCLC suggest that subgroups of patients could benefit differently from nivolumab according to their EGFR mutational status and smoking habits. These results warrant further investigation.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Garassino MC, Gelibter AJ, Grossi F, et al. Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients. J Thorac Oncol. 2018. PMID: 29730379. doi:10.1016/j.jtho.2018.04.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。